Taysha Gene Therapies Reports Q3 2026 GAAP EPS of -$0.10, Exceeding Estimates
Taysha Gene Therapies (TSHA) reported third-quarter earnings for the period ending September 30, 2026, delivering a GAAP earnings per share (EPS) of -$0.10. This result outperformed market expectations by $0.03. The biotechnology company maintains a strong liquidity position with $422.8 million in cash and cash equivalents as of the end of the quarter. Management stated that these current financial resources are expected to fund planned operating expenses and capital requirements through at least the second half of 2028.
Tickers: $TSHA